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Despite of incredible advances in the diagnosis and treatment
of various diseases, the incidence, prevalence, morbidity and
mortality resulting from these diseases continue to escalate.
Regardless, the wealth of information in internet, latest re-
search trends, and many other health databases and increasing
number of drugs available in the market, the progress to re-
duce medical need and disease burden is low in both developed
and under developed countries. For ages, pharmaceutical
products have been one of the main therapeutics to the major-
ity of the less privileged population. The potential of the drugs
has attracted the attention of the developed world, to tap their
beneﬁts to identify better and safe drugs to combat human dis-
eases, while in the poor nations these products continue to pro-
vide health beneﬁts to the diversiﬁed categories of patients
(Fura, 2006; Gyo¨rgy and Gergely, 2006). The combined efforts
of all public and private R&Ds worldwide bring around only
few drugs directed against completely novel mechanisms suc-
cessfully to market each year. Most drugs have had some ther-
apeutic beneﬁt, and some had phenomenal impact on
mortality and morbidity, such as the anti-tumor agents. How-
ever, in many diseases, for e.g. HIV, Diabetes, and Cancer the
cure has not been identiﬁed yet. The impact of genomics and
proteomics is additionally creating an explosion in the number
of drug targets. Today’s drug therapies are based solely on
approximately 500 biological targets, while, in 10 years’ time,
the number of targets could well reach 10,000. The increasing
demand for new small molecules led to the invention of new
technologies in the ﬁeld of Pharmaceutical Sciences. Ever-
increasing understanding of trends in pharmaceutical research,
the community continues to struggle with ﬁnding solutions to
identify lead molecules (William and Lloyd, 1998; Stephen
et al., 2002). The present study is focused on an oil rich country
of Middle East, the Kingdom of Saudi Arabia. With emerging
globalization of science and education, the challenge of educa-
tion and research needs in Saudi Arabia has opened new fron-
tiers. As it is moving forward in most of the areas of research
and setting up many research centers all over the country,
majority of Saudi universities’ prime interest is at advancing
research in individual ﬁelds and enhancing the research atmo-
sphere (AlAli, 2000; Simon and Yousif, 2012). The greatest
breakthrough during recent years is expanding the role of
pharmacists in the developing countries (Yousif, 2011). Saudi
Arabia sets as an example of identifying the primary role in
clinical pharmacy, drug discovery and research. Hence,pharmaceutical research is at the forefront and one of the stra-
tegic priorities in Saudi Arabia. Our main aim is to study and
analyze the research output of Saudi Arabia and to identify
highly productive institutes and authors.
Few scientometric studies have been published in this
area. Reddy and Mahesh Kumar (2006) provide a sciento-
metric analysis of world papers published by 57 countries
in 10 major sub-specialities appearing in three leading inter-
national journals during the ten year period. Dotson et al.
(2011) analyzed changes in the authorship and characteristics
of articles in pharmacy journals during the 20 year period. In
the ﬁeld of bibliometrics of country output in pharmacology
only a few studies have been carried out on India(Kaur and
Gupta, 2009; Ahila et al., 2011; Gupta et al., 2011), China
(Li et al., 2010) and Spain (Bordon and Barrigon, 2005)
which deal with different facets of pharmacological research,
its growth, global publication share and rank, international
collaboration, institutional and authors productivity proﬁle,
etc.1.1. Objectives
The main objective of present analysis in this paper is to ana-
lyze the Saudi Arabian contribution in the pharmaceutical re-
search during the last 10 years from 2001–10 with a view: (i) to
study the productivity proﬁle of the world’s top 15 most pro-
ductive countries; (ii) to study the Saudi Arabian research out-
put, citation impact, and international collaboration share and
identify the leading collaborating partner countries; (iii) to
study the contribution and citation impact of its most produc-
tive institutions & authors; (iv) to study the media of commu-
nication in most productive journals, and (v) to study the
characteristics of highly cited papers.2. Methodology and source used
This study was undertaken based on the publication data from
Saudi Arabia and also identiﬁes the top 15 most productive
countries in the ﬁeld of pharmaceutical research. Data for
the present study were retrieved from the Scopus international
multidisciplinary bibliographical database [http://www.sco-
pus.com/search/] for the last ten years (2001–2010). The search
strategy string used to retrieve the main data on research out-
put, institutions, authors and major journals of Saudi Arabia
is as follows:
Table 1 Publications output, share & rank of top 15 countries in pharmaceutical sciences, 2001–10.
Country Publications output Publications share Publications rank
2001–05 2006–10 2001–10 2001–05 2006–10 2001–10 2001–05 2006–10 2001–10
USA 68351 83676 152027 24.59 24.41 24.49 1 1 1
China 11859 34529 46388 4.27 10.07 7.47 5 2 2
Japan 22602 23466 46068 8.13 6.85 7.42 2 4 3
UK 18602 21684 40286 6.69 6.33 6.49 3 5 4
Germany 16286 18751 35037 5.86 5.47 5.64 4 6 5
India 9449 23897 33346 3.40 6.97 5.37 8 3 6
Italy 10280 13992 24272 3.70 4.08 3.91 7 7 7
France 10510 12042 22552 3.78 3.51 3.63 6 8 8
Canada 8298 9885 18183 2.99 2.88 2.93 10 9 9
Spain 8442 9227 17669 3.04 2.69 2.85 9 10 10
South Korea 5356 9188 14544 1.93 2.68 2.34 12 11 11
Brazil 3918 7879 11797 1.41 2.30 1.90 14 12 12
Netherlands 5591 5950 11541 2.01 1.74 1.86 11 14 13
Australia 4823 6671 11494 1.74 1.95 1.85 13 13 14
Switzerland 3629 4736 8365 1.31 1.38 1.35 15 15 15
World 277907 342774 620681 100.00 100.00 100.00
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AFFIL(saudi arabia) AND PUBYEAR> 2000 AND
PUBYEAR< 2011 AND (LIMIT-TO(SUBJAREA,
‘‘PHAR’’)) AND (LIMIT-TO(AF-ID, ‘‘King Saud University
College of Pharmacy’’60001933))
AFFIL(saudi arabia) AND PUBYEAR> 2000 AND
PUBYEAR< 2011 AND (LIMIT-TO(SUBJAREA,
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M’’ 8605268800))
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PUBYEAR< 2011 AND (LIMIT-TO(SUBJAREA, ‘‘PHAR’’))
AND (LIMIT-TO(EXACTSRCTITLE, ‘‘Journal of Pharmaceu-
tical and Biomedical Analysis’’))
For citations data, three year, two year and one year cita-
tions window has been used for computing average citations
per paper from Saudi Arabia during 2001–2008, 2009 and
2010. For searching and calculating the total international col-
laborative papers, a separate search strategy, which combines
Saudi Arabia’s collaboration with 140 major countries, was
also prepared.
3. Analysis
3.1. Global publication output in pharmaceutical sciences
The publication output of the top 15 most productive coun-
tries ranges from 1.35% to 24.49% during 2001–10. The larg-
est contribution is made by USA with 24.49% share, followed
far behind by China (7.47% share), Japan (7.42% share), U.K
(6.49% share), Germany (5.64% share), India (5.37% share),
Italy, France, Canada, Spain and South Korea (with publica-
tion share varying from 2.34% to 3.91%), Brazil, Netherlands,
Australia and Switzerland (with publication share varying
from 1.35% to 1.90%). The publication share has increased
in China by 5.8%, followed by India (3.57%), Brazil
(0.89%), South Korea (0.75%), Italy (0.38%), Australia
(0.21%) and Switzerland (0.07%), as against decrease by
1.28% in Japan, followed by Germany (0.39%), U.K(0.36%), Spain (0.35%), France and Netherlands (0.27%
each), USA (0.18%) and Canada (0.11%) from 2001–05 to
2006–10. In terms of publication rank, countries which have
improved their global rank are China (from 5th to 2nd), India
(from 8th to 3rd), Canada (from 10th to 9th), South Korea
(from 12th to 11th) and Brazil (from 14th to 12th), in contrast
to countries losing their rank such as Japan (from 2nd to 4th),
UK (from 3rd to 5th), Germany (from 4th to 6th), France
(from 6th to 8th), Spain (from 9th to 10th) and Netherlands
(from 11th to 14th) from 2001–05 to 2006–10. For other coun-
tries, global publications rank has remained the same during
the above mentioned period (Table 1).
3.2. Saudi Arabia’s publication output, citation impact and
international collaboration
The research output of Saudi Arabia in pharmaceutical science
consists of 1386 papers during 2001–10, which has increased
from 111 papers in 2001 to 301 papers in 2010, registering
an annual average growth rate of 14.21%. The cumulative re-
search output of Saudi Arabia in pharmaceutical science has
increased from 567 papers during 2001–05 to 819 papers dur-
ing 2006–10, witnessing a growth rate of 44.44%. The global
share of Saudi Arabia was only 0.50% during 2001–10. The
average citation impact per paper registered for total papers
in pharmaceutical science of Saudi Arabia was 3.36, which
marginally decreased from 3.38 during 2001–05 to 3.35 during
2006–10 (Table 2).
The international collaborative output of Saudi Arabia in
pharmaceutical science consists of 562 papers, constituting
40.55% share of its total publications output during 2001–
10. The share of international collaborative output of Saudi
Arabia has increased from 32.45% during 2001–05 to
46.15% during 2006–10 (Table 2). Of the total international
collaborative papers published by Saudi Arabia in pharmaceu-
tical science with different countries, 15 countries have pub-
lished 8 or more papers. The largest number of international
collaborative papers (247 papers, 43.95% share) of Saudi
Arabia is published with Egypt, followed by USA (88 papers,
15.66% share), India (70 papers, 12.46% share), U.K.
Table 2 Saudi Arabia: Research output, citation impact and international collaborative papers in pharmaceutical science 2001–10.
=Publication year Total papers Total citations ACPP International
collaborative papers (ICP)
Share of ICP Total citations
(of ICP)
ACPP (of ICP)
2001 111 315 2.84 25 22.52 118 4.72
2002 122 416 3.41 34 27.87 130 3.82
2003 120 396 3.30 49 40.83 203 4.14
2004 102 340 3.33 41 40.20 150 3.66
2005 112 449 4.01 35 31.25 224 6.40
2006 96 470 4.90 21 21.88 125 5.95
2007 115 590 5.13 36 31.30 218 6.06
2008 132 524 3.97 57 43.18 288 5.05
2009 175 560 3.20 78 44.57 344 4.41
2010 301 600 1.99 186 61.79 433 2.33
2001–05 567 1916 3.38 184 32.45 825 4.48
2006–10 819 2744 3.35 378 46.15 1408 3.72
20001–10 1386 4660 3.36 562 40.55 2233 3.97
218 I. Alhaider et al.(40 papers, 7.12% share), Germany and Japan (20 papers,
3.56% share each), Canada (19 papers, 3.38% share), Sudan
(16 papers, 2.85% share), etc. The international collaborative
share of Saudi Arabia has increased by 11.21% with Egypt,
followed by India (8.82%), Pakistan (5.03%), Canada
(2.6%), Sweden (2.38%), Japan (0.44%), Sudan (0.19%) and
U.K (0.07%), as against decrease by 7.42% by USA, followed
by Turkey (5.73%), Kuwait (1.93%), Jordan (1.67%), Belgium
(1.66%), Germany (0.36%) and United Arab Emirates
(0.04%) from 2001–05 to 2006–10 (Table 3).
3.3. Focus of pharmacological research
3.3.1.Organs
If we study organ-wise the focus of research, we can get ideas
regarding the nature of pharmaceutical research being probed
in Saudi Arabia. The maximum focus of pharmaceutical re-
search in Saudi Arabia during 2001–10 has been on liver (with
169 papers), followed by kidney (102 papers), heart (84), mus-
cle (56), stomach (49), skin (48), brain (43), breast (42), eye
(16), artery (14), pancreas (12), ear (8), throat (5), genital (4),
feet (3) and neck (2).
3.3.2. Disease
The maximum output of pharmaceutical research has been re-
ported on cancer (with 149 papers), followed by heart diseases
(104 papers), diabetes (61 papers), respiratory infection (26 pa-
pers), blood disorders (22), tuberculosis (15), depression (14
papers), HIV/AIDS (10), diarrhea (10), epilepsy (10 papers),
pneumonia (9), malaria (9), hepatitis (9 papers), cirrhosis (6),
leishmaniasis (6), etc.
3.3.3. Pharmacological activity
The largest pharmaceutical activity reported in the literaturewas on
enzyme activity (with 125 papers), followed by anti-oxidant activity
(87 papers), anti-neoplastic activity (70 papers), anti-inﬂammatory
activity (54 papers), anti-microbial activity (40 papers), anti-bacte-
rial activity (27 papers), anti-fungal activity (22 papers), analgesic
activity (20 papers), anti-viral activity (17 papers), etc.
3.4. Most productive organizations – contribution and impact
The top 15 most productive Saudi Arabian organizations in-
volved in pharmaceutical research together have published1336 during 2001–10. The publications proﬁle of these 15 Sau-
di Arabian organizations along with their research output,
citations received and h-index values are presented in Table 4.
These 15 organizations together have contributed 96.39%
share (with 1336 papers) in the cumulative publications output
of Saudi Arabia, with an average of 89.6 papers per organiza-
tion. The productivity of these organizations varies from 14 to
505 during 2001–10. Four organizations have contributed
more than the average productivity of all organizations. These
are King Saud University, Coll of Pharmacy with 505 papers,
followed by King Saud University, (185 papers), King Faisal
Specialist Hosp & Research Centre (170 papers) and King Ab-
dul Aziz University, Jeddah (109 papers). The average citation
per paper registered by the total papers of these 15 Saudi Ara-
bian organizations was 3.41 (varying from 1 to 5.21) during
2001–10. Five organizations have registered higher impact
than the group average of all organizations. These are King
Faisal Specialist Hosp & Reseach Centre with an average cita-
tion per paper of 5.21, followed by Taibah University (5.03),
King Saud University, Medical Coll (4.79), King Fahd Univer-
sity of Petroleum & Minerals (4.76) and King Khalid Univer-
sity (3.50). The average h-index of all Saudi Arabian
organizations was 10.60 (varying from 4 to 27). Six organiza-
tions have scored a higher value of h-index than the average
value of h-index of all organizations. These are King Saud
University, Coll of Pharmacy with h-index value of 27, fol-
lowed by King Faisal Specialist Hosp & Research Centre
(20), King Saud University (16), King Saud University, Med-
ical Coll (14), King Abdulaziz University (12) and King Fahd
University of Petroleum & Minerals (11) (Table 4).
3.5. Most productive authors – contributions and impact
As seen in Table 5, it is clear that the top 15 contributors from
Saudi Arabia are afﬁliated to the following organizations:
King Saud Univ, Riyadh (12 authors), Al Qaseem University
(one author), Armed Forces Hosp, Riyadh (one author) and
King Abdulaziz University (one author). The 15 most produc-
tive authors have together contributed a total of 419 papers,
constituting 30.23% share of the total output of Saudi Arabia
and registering an average productivity per author of 27.93.
Four authors have contributed more than the average produc-
tivity of all authors. They are H.Y. Aboul-Enein with 85 pa-
pers, followed by A. Al-Shabanah (43 papers), I.A. Alsarra
Table 3 Saudi Arabia: International collaborative papers & share in pharmaceutical science 2001–10.
Period International collaborative publications Share of international collaborative papers
2001–05 2006–10 2001–10 2001–05 2006–10 2001–10
Egypt 67 180 247 36.41 47.62 43.95
USA 38 50 88 20.65 13.23 15.66
India 12 58 70 6.52 15.34 12.46
UK 13 27 40 7.07 7.14 7.12
Germany 7 13 20 3.80 3.44 3.56
Japan 6 14 20 3.26 3.70 3.56
Canada 3 16 19 1.63 4.23 3.38
Pakistan 0 19 19 0.00 5.03 3.38
Sudan 5 11 16 2.72 2.91 2.85
Turkey 12 3 15 6.52 0.79 2.67
Jordan 6 6 12 3.26 1.59 2.14
Belgium 5 4 9 2.72 1.06 1.60
United Arab Emirates 3 6 9 1.63 1.59 1.60
Sweden 0 9 9 0.00 2.38 1.60
Kuwait 5 3 8 2.72 0.79 1.42
Total 184 378 562 100.00 100.00 100.00
Table 4 Productivity and citation impact of top 15 Saudi Arabian organizations in pharmaceutical science, 2001–10.
Name of the Institution TP TC ACPP H-Index ICP %ICP HCP %HCP
King Saud University, Coll of Pharmacy 505 1626 3.22 27 160 31.68 0 0
King Saud University 185 580 3.14 16 85 45.95 1 0.54
King Faisal Specialist Hosp & Reseach Centre 170 885 5.21 20 82 48.24 1 0.59
King Abdulaziz University 109 351 3.22 12 51 46.79 0 0.00
King Saud University, Coll of Science 67 170 2.54 10 16 23.88 0 0.00
King Faisal University 59 96 1.63 8 28 47.46 1 1.69
King Saud University, Medical Coll 53 254 4.79 14 11 20.75 0 0.00
Taibah University 37 186 5.03 7 16 43.24 0 0.00
Riyadh Military Hospital 35 82 2.34 7 5 14.29 0 0.00
King Fahd University of Petroleum & Minerals 25 119 4.76 11 9 36.00 0 0.00
King Khalid University 24 84 3.50 6 16 66.67 0 0.00
Al Qasim University 21 28 1.33 4 9 42.86 0 0.00
King Khalid University Hosp 17 56 3.29 7 1 5.88 0 0.00
Um Al Qura University 15 15 1.00 4 3 20.00 0 0.00
Ministry of Health, Saudi Arabia 14 21 1.5 6 5 35.7 0 0
Total 1336 4553 3.41 10.6 497 37.2 3 0.22
Total Saudi Arabia Output 1386
Share of the Top 14 Organizations in total Saudi Arabia Output 96.39
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contributed by the top 15 authors have received 1548 citations,
registering a citation impact per paper of 3.69 (varying from
1.83 to 7.47). Seven authors have registered higher impact than
the average citation impact per paper of all authors. They are
A.A.M. Abdel-Aziz with a citation impact per paper of 7.47,
followed by B.H. Ali (6.17), S.A. Rostom (6.13), A.A. Al-Maj-
ed (4.56), F.S. El-Feraly (4.19) and H.Y. Aboul-Enein (3.82).
The top 15 most productive authors have registered an average
h-index of 9.06 (varying from 4 to 16). Five authors have reg-
istered higher value of h-index than the average value of h-in-
dex of all authors. They are H.Y. Aboul-Enein with a h-index
value of 16, followed by A. Al-Shabanah (14), A.A. Al-Majed
(12), B.H. Ali (11) and F.F. Belal (11). The 15 authors have re-
ceived an average international collaborative share of 31.98%
(varying from 0.0% to 93.75%). Four authors have received
higher share than the average share of international collabora-
tive papers of all authors. They are F.S. El-Feraly with inter-
nationally collaborative papers share of 93.75%, followed byA.A.M. Abdel-Aziz (73.33%), H.Y. Aboul-Enein (67.06%)
and S.A. Rostom (46.67%) [Table 5].
3.6. Research communication in high productive journals
The 15 most productive domestic and foreign journals publish-
ing Saudi Arabian research papers together contributed 524
papers in pharmaceutical science, which accounted for
37.81% of the total output of Saudi Arabia during 2001–10.
The cumulative share of these 15 journals in total publications
output of Saudi Arabia in pharmaceutical science has de-
creased from 45.50% during 2001–05 to 32.48% during
2006–10 (Table 6).3.7. Highly cited papers
There are 19 Saudi Arabian papers, which have received 50
or more citations since their publication till 22 February
Table 5 Productivity and Citation Impact of Top 15 Saudi Arabian Authors in Pharmaceutical Science, 2001–10.
S. No Name Address TP TC ACPP H-Index ICP % ICP
1. H.Y. Aboul-Enein King Saud Univ, Coll of Pharm 85 325 3.82 16 57 67.06
2. A. Al-Shabanah King Saud Univ, Coll of Pharm 43 147 3.42 14 1 2.33
3. I.A. Alsarra King Saud Univ, Coll of Pharm 36 76 2.11 8 5 13.89
4. F.F.Belal King Saud Univ, Coll of Pharm 30 84 2.80 11 9 30.00
5 A.A. Al-Majed King Saud Univ, Coll of Pharm 27 123 4.56 12 0 0.00
6. J.S. Mossa King Saud Univ, Coll of Pharm 26 75 2.88 7 3 11.54
7. M.A. Al-Omar King Saud Univ, Coll of Pharm 26 81 3.12 8 8 30.77
8. B.H. Ali Al Qaseem Univ, Dept Vet Med 23 142 6.17 11 6 26.09
9. H.I. El-Subbagh King Saud Univ, Coll of Pharm 23 86 3.74 8 7 30.43
10. F.K. Alanazi King Saud Univ, Coll of Pharm 19 50 2.63 5 3 15.79
11. H.A. Khan Armed Forces Hosp, Riyadh 18 33 1.83 4 1 5.56
12. N.S. Barakat King Saud Univ, Coll of Pharm 17 55 3.24 6 1 5.88
13. F.S. El-Feraly King Saud Univ, Coll of Pharm 16 67 4.19 9 15 93.75
14. S.A. Rostom King Abdulaziz Univ, Deptt Pharm Chem 15 92 6.13 9 7 46.67
15. A.A.M. Abdel-Aziz King Saud Univ, Coll of Pharm 15 112 7.47 8 11 73.33
Total 419 1548 3.69 9.06 134 31.98
Total Output of Saudi Arabia 1386
Share of Top 15 Authors in Total Output of Saudi Arabia 30.23
Table 6 Proﬁle of top 15 Journals where Saudi Arabian scientists have published in pharmaceutical science, 2001–10.
S. No. Name of the journal Number of papers IF 2010
2001–05 2006–10 2001–10
1 Saudi Pharmaceutical Journal 76 69 145 0.13
2 Biosciences Biotechnology Research Asia 6 37 43
3 Journal of Pharmaceutical and Biomedical Analysis 30 12 42 2.73
4 European Journal of Medicinal Chemistry 3 34 37 3.19
5 Archiv Der Pharmazie 17 15 32
6 Farmaco 28 0 28
7 Scientia Pharmaceutica 14 13 27
8 International Journal of Pharmacology 0 27 27
9 Biomedical Chromatography 17 10 27 1.54
10 Phytotherapy Research 15 7 22
11 Pharmacological Research 20 2 22 3.61
12 Food and Chemical Toxicology 4 16 20 2.602
13 Pharmazie 16 4 20 0.869
14 Journal of Medicinal Plants Research 0 17 17 0.879
15 Journal of Ethnopharmacology 12 3 15 2.466
Total 258 266 524 258
Total Output of Saudi Arabia 567 819 1386 567
Share of top 15 journals in Saudi Arabia Total Output 45.50 32.48 37.81 45.50
220 I. Alhaider et al.2012 (Table 7). These are referred here as high cited papers.
Of the 19 high cited papers, 10 have appeared as articles
and 9 as reviews. Of the 19 high cited papers, 5 were inter-
national (4 bilateral and 1 multilateral) collaborative. Of the
19 high cited papers, 1 paper falls in the citation range of
201–227, 2 papers fall in the citation range of 100–199
and 16 papers fall in the citation range of 50–99. These 19
high cited papers have received 1566 citations, with an aver-
age of 82.42 citations per paper and the citation range of
these papers varies from 50 to 227. These 19 high cited pa-
pers involve 7 Saudi Arabian organizations. Among them,
the largest number of papers (6) is contributed by King
Saud University, College of Pharmacy, followed by King
Faisal Specialist Hosp & Research Center (5 papers), King
Abdul-Aziz University (3 papers), King Saud University,
Department of Veterinary Medicine (2 papers), King FaisalUniversity, College of Medicine (1 paper), Armed Forces
Hospital, Department of Internal Medicine, Riyadh (1 pa-
per) and Taibah University, Department of Clinical Bio-
chemistry (1 paper).
These 19 high cited papers have appeared in 15 journals.
Among them, the largest number of papers (2) each of which
appeared in Alimentary Pharmacology and Therapeutics, Cur-
rent Drug Metabolism, European Journal of Medicinal Chem-
istry and Pharmacological Research and 1 paper each in
Bioorganic and Medicinal Chemistry, Chirality, European
Journal of Pharmaceutical Sciences, European Journal of
Pharmaceutics and Biopharmaceutics, Food and Chemical
Toxicology, International Journal of Pharmaceutics, Journal
of Ethnopharmacology, Journal of Pharmaceutical and Bio-
medical Analysis, Medicinal Research Reviews, Phytotherapy
Research and Tetrahedron.
Table 7 List of highly cited papers by Saudi Arabian authors in pharmaceutical science, 2001–10.
Authors Title Source No. of Citations
Ali B.H., Blunden G. Pharmacological and toxicological properties of
Nigella sativa
Phytotherapy Research 2003,
17(4), 299–305
227
Ghanem A. Trends in lipase-catalyzed asymmetric access to
enantiomerically pure/enriched compounds
Tetrahedron 2007, 63(8), 1721–54 134
Al-Ghamdi M.S. The anti-inﬂammatory, analgesic and antipyretic
activity of Nigella sativa
Journal of Ethnopharmacology
2001, 76(1), 45–48
122
Khuroo M.S., Khuroo
N.S., Farahat K.L.C.,
Khuroo Y.S., Soﬁ A.A.,
Dahab S.T.
Meta-analysis: Endoscopic variceal ligation for
primary prophylaxis of esophageal variceal bleeding
Alimentary Pharmacology and
Therapeutics 2005, 21(4), 347–361
93
Ghanem A., Aboul-
Enein H.Y.
Application of lipases in kinetic resolution of
racemates
Chirality 2005, 17(1), 1–15 89
Okarvi S.M. Peptide-Based Radiopharmaceuticals: Future Tools
for Diagnostic Imaging of Cancers and Other
Diseases
Medicinal Research Reviews 2004,
24(3), 357–97
87
El-Kamel A.H. In vitro and in vivo evaluation of Pluronic F127-
based ocular delivery system for timolol maleate
International Journal of
Pharmaceutics 2002, 241(1), 47–55
86
Saad S.Y., Najjar T.A.,
Al-Rikabi A.C.
The preventive role of deferoxamine against acute
doxorubicin-induced cardiac, renal and hepatic
toxicity in rats
Pharmacological Research 2001,
43(3), 211–18
78
Rostom S.A.F., Shalaby
M.A., El-Demellawy
M.A.
Polysubstituted pyrazoles, part 5.1. Synthesis of new
1-(4-chlorophenyl)-4-hydroxy-1H-pyrazole-3-
carboxylic acid hydrazide analogs and some derived
ring systems. A novel class of potential antitumor
and anti-HCV agents
European Journal of Medicinal
Chemistry 12 Nov 2003, 38, 959–74
67
Belal F., Al-Zaagi I.A.,
Gadkariem E.A.,
Abounassif M.A.
A stability-indicating LC method for the
simultaneous determination of ramipril and
hydrochlorothiazide in dosage forms
Journal of Pharmaceutical and
Biomedical Analysis 2001, 24(3),
335–42
67
Sanai F.M., Bzeizi K.I. Systematic review: Tuberculous peritonitis -
Presenting features, diagnostic strategies and
treatment
Alimentary Pharmacology and
Therapeutics 2005, 22(8), 685–700
65
El Maghraby G.M.,
Barry B.W., Williams
A.C.
Liposomes and skin: From drug delivery to model
membranes
European Journal of
Pharmaceutical Sciences 5 April
2008, 34, 203–22
64
Rostom S.A.F. Synthesis and in vitro antitumor evaluation of some
indeno[1,2-c]pyrazol(in)es substituted with
sulfonamide, sulfonylurea(-thiourea)
pharmacophores, and some derived thiazole ring
systems
Bioorganic and Medicinal
Chemistry 2006, 14(19), 6475–85
61
Sheweita S.A.,
Tilmisany A.K.
Cancer and phase II drug-metabolizing enzymes Current Drug Metabolism 2003,
4(1), 45–58
59
Kadi A.A., El-Brollosy
N.R., Al-Deeb O.A.,
Habib E.E., Ibrahim
T.M., El-Emam A.A.
Synthesis, antimicrobial, and anti-inﬂammatory
activities of novel 2-(1-adamantyl)-5-substituted-
1,3,4-oxadiazoles and 2-(1-adamantylamino)-5-
substituted-1,3,4-thiadiazoles
European Journal of Medicinal
Chemistry 2007, 42(2), 235–42
56
Ali B.H. Agents ameliorating or augmenting experimental
gentamicin nephrotoxicity: Some recent research
Food and Chemical Toxicology
2003, 41(11), 1447–52
56
Al-Majed A.A.,
Mostafa A.M.,
Al-Rikabi A.C.,
Al-Shabanah O.A.
Protective eﬀects of oral arabic gum administration
on gentamicin-induced nephrotoxicity in rats
Pharmacological Research 2002,
46(5), 445–451
55
Sheweita S.A.,
Tilmisany A.M.,
Al-Sawaf H.
Mechanisms of male infertility: Role of antioxidants Current Drug Metabolism 2005,
6(5), 495–501
50
Alsarra I.A., Bosela
A.A., Ahmed S.M.,
Mahrous G.M.
Proniosomes as a drug carrier for transdermal
delivery of ketorolac
European Journal of
Pharmaceutics and
Biopharmaceutics 2005, 59(3),
485–90
50
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Saudi Arabia in pharmaceutical research has produced 1386
papers during 2001–10, increasing from 111 papers in 2001to 301 papers in 2010 and witnessing an annual productivity
of 138.6 and annual average growth rate of 14.21%. Its cita-
tion impact was 3.36 during 2001–10, which decreased from
3.38 to 3.35 from 2001–05 to 2006–10. The share of its interna-
222 I. Alhaider et al.tional collaborating papers output, constitute 40.55% of its
output, increasing from 32.45% during 2001–05 to 46.15%
during 2006–10. The largest number of international collabo-
rative papers (with 43.95% share) of Saudi Arabia comes with
Egypt, followed by USA (15.66% share), India (12.46%
share), U.K (7.12% share), Germany and Japan (3.56% share
each), Canada (3.38% share), Sudan (2.85% share), etc. The
maximum focus of pharmaceutical research was on cancer
(with 149 papers), followed by heart diseases (104 papers), dia-
betes (61 papers), respiratory infection (26 papers), blood dis-
orders (22), tuberculosis (15), depression (14 papers), HIV/
AIDS (10), diarrhea (10), epilepsy (10 papers), pneumonia
(9), malaria (9), hepatitis (9 papers), etc. In terms of pharma-
cological activity, the largest research was focused on enzyme
activity (with 125 papers), followed by anti-oxidant activity (87
papers), anti-neoplastic activity (70 papers), anti-inﬂammatory
activity (54 papers), anti-microbial activity (40 papers), anti-
bacterial activity (27 papers), anti-fungal activity (22 papers),
analgesic activity (20 papers), anti-viral activity (17 papers),
etc. The top 15 most productive Saudi Arabian organizations
involved in pharmaceutical research together have published
1336 during 2001–10, accounting for 96.39% share in the
cumulative publications output of Saudi Arabia, with an aver-
age of 89.6 papers per organizations. The average citation per
paper and average h-index registered by the total papers of
these 15 Saudi Arabian organizations were 3.41 (varying from
1 to 5.21) and 10.60 (varying from 4 to 27). The 15 most pro-
ductive authors have together contributed a total of 419 papers
(varying from 15 to 85), constituting 30.23% share of the total
output of Saudi Arabia and registering an average productivity
per author of 27.93. The average citation per paper and aver-
age h-index registered by the total papers of these 15 Saudi
Arabian authors were 3.69 (varying from 1.83 to 7.47) and
9.06 (varying from 4 to 16). The top 15 journals where Saudi
Arabian scientists have published together contributed 524 pa-
pers in pharmaceutical science, which accounted for 37.81% of
the total output of Saudi Arabia during 2001–10, decreasing
from 45.50% during 2001–05 to 32.48% during 2006–10.
There are 19 Saudi Arabian papers, which have received 50
or more citations since their publication. These 19 high cited
papers have received an average of 82.42 citations per paper
and the citation range of these papers varies from 50 to 227.
These 19 high cited papers involve 7 Saudi Arabian organiza-
tions and have appeared in 15 journals.
5. Conclusion
There is a need to improve the number of publications in order
to measure Saudi Arabia’s research in pharmaceutical sciences.
As most of the universities and major organizations are speed-
ing up in a setting research atmosphere all over country it is
obvious, based on fact of Globalization of Research and edu-
cation, Saudi Arabia will emerge as one of the productive
countries in terms of pharmaceutical research. Rigorous ef-
forts are still necessary with respect to research productivity,
international collaborations, multi cultured research environ-ment, cutting edge drug discovery and quality research. It is
now clear, that the number of research output in terms of pub-
lications has seen a tremendous growth in last 2–3 years. We
foresee that Saudi Arabia will become the most productive
country in the near future.
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